Clinical trials: Type 2 Diabetes
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus
A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily…
- Trial name
- NCT01582308
- Testing
- Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Nephropathy
Nephropathy In Type 2 Diabetes and Cardio-renal Events
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic…
- Trial name
- NID-2 (NCT00535925)
- Testing
- SoC therapy, irbesartan, ramipril
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- University of Campania Luigi Vanvitelli
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
- Trial name
- NCT00286455
- Testing
- Alogliptin
- Where
- 67 sites in United States, Argentina and 16 more
- Volunteers
- 329 people
- Sponsor
- Takeda
Non-Insulin-dependent Diabetes Mellitus
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2)…
- Trial name
- NCT01582282
- Testing
- 3.4 g psyllium BID, 6.8g psyllium BID
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Procter and Gamble
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of LY2405319 in Participants With Type 2 Diabetes
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days.
- Trial name
- NCT01869959
- Testing
- LY2405319
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as…
- Trial name
- NCT01515657
- Testing
- PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- PLx Pharma
Type 2 Diabetes Mellitus
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in…
- Trial name
- NCT00789750
- Testing
- Colesevelam, Pioglitazone
- Where
- 141 sites in United States
- Volunteers
- 562 people
- Sponsor
- Daiichi Sankyo
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
- Trial name
- TRENDS (NCT03014479)
- Testing
- Trelagliptin, Daily DPP-4 inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 219 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Type2 Diabetes
OP5-005 Using Omnipod 5 in Adults With Type 2
This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.
- Trial name
- SECURE-T2D (NCT05815342)
- Testing
- Omnipod 5 Automated Glucose Control System
- Where
- 21 sites in United States
- Volunteers
- 343 people
- Sponsor
- Insulet Corporation
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effect of DPP4 Inhibition on Vasoconstriction
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an…
- Trial name
- NCT02639637
- Testing
- Sitagliptin, Neuropeptide Y, Enalaprilat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypogonadism
Testosterone Replacement in Men With Diabetes and Obesity
The purpose of this study is to examine the effect of having testosterone deficiency in men with diabetes and with obesity. The study will also evaluate the effect of testosterone therapy.
- Trial name
- NCT01127659
- Testing
- testosterone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 2
A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients
This study is designed to look at if a basal bolus regimen of insulin lispro protamine suspension (ILPS) provides the same glycemic control as a basal bolus regimen of insulin glargine (when one basal bolus regimen is injected…
- Trial name
- NCT00666718
- Testing
- Insulin Glargine, Insulin Lispro Protamine Suspension (ILPS), Insulin Lispro
- Where
- 50 sites in Belgium, Czechia and 8 more
- Volunteers
- 374 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.